Collaborative Development

New drug development is the core business of ENIMMUNE. Our mission is to obtain drug licenses and control sales outlets for innovative or industrially valuable new drugs or proteins and to quickly commercialize them through the division of labor. As a participant in the biotechnology industry, we operate at less risk based on an innovative business model.

Our Partners

Adimmune Corporation / Academia Sinica / National Health Research Institutes / National Taiwan University Hospital and Hsin-Chu Branch / China Medical University Hospital / Linkou Chang Gung Memorial Hospital / Taipei Veterans General Hospital & Taichung Veterans General Hospital / Pasteur Institute (Vietnam, HCMC) / Changhua Christian Hospital

Adimmune Corporation

Mass production

With years of experience in mass production, Adimmune Corporation adopts a GMP system that passes the audits of health authorities such as EMA (EU), FDA (US), AVISA (Brazil), etc. Adimmune Corporation is commissioned by the Company to produce EV71 vaccine.

National Health Research Institutes

Screening of CA16 vaccine strain

National Institute of Infections Diseases and Vaccinology (NIIDV)

Experienced in developing novel vaccines and biologicals, the NIIDV adopts animal experimental models and enterovirus subtypes and neutralization test platforms to effectively screen a variety of CA16 strains identified in Taiwan as candidate strains for mass production.

Pasteur Institute (Vietnam,HCMC)

Phase III clinical trials of EV71 vaccine

Vietnam is a member state of the Association of Southeast Asian Nations (ASEAN). The Institut Pasteur of Vietnam is commissioned to conduct the Phase III clinical trial of EV71 vaccine in hopes of protecting the health of the public.

Partnership

to top